Stockscreener 앱 받기
1.78
1.14%
0.02
Quince Therapeutics Inc 주식(QNCX)의 최신 뉴스
Research Analysts Offer Predictions for QNCX FY2024 Earnings - Defense World
Brookline Capital Management Predicts QNCX FY2024 Earnings - MarketBeat
Quince Therapeutics initiated with a Buy at Brookline - MSN
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Brookline Capital Management Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Brookline initiates coverage on Quince Therapeutics shares, sees favorable risk-reward - Investing.com
Brookline Capital Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Increase in Short Interest - MarketBeat
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Short Interest Down 23.8% in November - MarketBeat
QNCX (Quince Therapeutics) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Critical Survey: Amgen (NASDAQ:AMGN) and Quince Therapeutics (NASDAQ:QNCX) - Defense World
QNCX stock touches 52-week high at $2.14 amid robust gains By Investing.com - Investing.com South Africa
Maxim Group Initiates Coverage of Quince Therapeutics (QNCX) with Buy Recommendation - MSN
QNCX stock touches 52-week high at $2.14 amid robust gains - Investing.com
Short Interest in Quince Therapeutics, Inc. (NASDAQ:QNCX) Rises By 23.0% - MarketBeat
QNCX Stock Soars to 52-Week High, Reaching $1.79 Amidst Strong Growth - Investing.com Australia
Quince Therapeutics regains Nasdaq compliance - Investing.com
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - Business Wire
Quince Therapeutics' EryDex Shows Promise in Phase 3 Ataxia Trial, Key Data Revealed | QNCX Stock News - StockTitan
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research - Business Wire
Quince Therapeutics reports positive safety data for EryDex - Investing.com India
Quince Therapeutics reports positive safety data for EryDex By Investing.com - Investing.com UK
Quince Therapeutics' EryDex Shows Promising Safety Data in Phase 3 A-T Trial | QNCX Stock News - StockTitan
Quince Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - XM
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group - MarketBeat
This Edison International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Raised to “Strong-Buy” at RODMAN&RENSHAW - Defense World
QNCX stock touches 52-week high at $1.44 amid market optimism - Investing.com UK
Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Rodman & Renshaw sets stock target, buy rating on Quince Therapeutics - Investing.com
US Penny Stocks To Watch In October 2024 - Yahoo Finance
Quince Therapeutics shares rated Buy at EF Hutton, optimistic about EryDex's potential - Investing.com Canada
Quince Therapeutics to Participate at Upcoming Investor Conferences - Business Wire
Quince Therapeutics (NASDAQ:QNCX) Shares Down 5.1% - Defense World
Finalist, Public Company, Medium: Christopher J. Senner, Exelixis Inc. - The Business Journals
Ataxia Telangiectasia Market Growth to Accelerate in Forecast - openPR
Quince Therapeutics, Inc. (NASDAQ:QNCX) CEO Dirk Thye Purchases 77,500 Shares - Defense World
Quince Therapeutics CEO acquires $107k in company stock - Investing.com
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
The Potential Rise in the Price of Quince Therapeutics Inc (QNCX) following insiders activity - Knox Daily
Healthy Upside Potential: Quince Therapeutics Inc (QNCX) - SETE News
Have you been able to find a good deal on Quince Therapeutics Inc’s shares? - US Post News
Charles S. Ryan Purchases 48,387 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Brendan Hannah Buys 30,845 Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock - Defense World
Quince Therapeutics COO Brendan Hannah buys $24,166 in company stock - Investing.com India
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 - MSN
Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex (NASDAQ:QNCX) - Seeking Alpha
Quince Therapeutics (NASDAQ:QNCX) Trading 1.5% Higher - Defense World
Quince reports data from Phase III Ataxia-Telangiectasia treatment trial - Clinical Trials Arena
2.88%
2.65%
자본화:
|
볼륨(24시간):